Pending Medicare Fee-Schedule Selection For Gene Tests Has Significant Implications – Consultant
10:00 EDT 6 Aug 2012 | Elsevier Business Intelligence
Which payment system should incorporate new molecular diagnostic codes? CMS’ decision could have unsettling results for some gene test makers.
Original Article: Pending Medicare Fee-Schedule Selection For Gene Tests Has Significant Implications – Consultant
More From BioPortfolio on "Pending Medicare Fee-Schedule Selection For Gene Tests Has Significant Implications – Consultant"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
